Immunological effects of sublingual immunotherapy: Clinical efficacy is associated with modulation of programmed cell death ligand 1, IL-10, and IgG4

Journal of Immunology

Volumn 185, Issue 12, 2010, Pages 7723-7730

  Piconi, Stefania ^a   Trabattoni, Daria ^a   Rainone, Veronica ^a   Borgonovo, Linda ^a   Passerini, Simone ^a   Rizzardini, Giuliano ^a   Frati, Franco ^b   Iemoli, Enrico ^a   Clerici, Mario ^c,d  

^a UNIVERSITY OF MILAN   (Italy)

^b Scientific Department Stallergenes   (Italy)

^c IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD86 ANTIGEN; IMMUNOGLOBULIN G4; INTERLEUKIN 10; INTERLEUKIN 4; PROGRAMMED DEATH 1 LIGAND 1;

ADULT; AGED; ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CYTOKINE PRODUCTION; DRUG EFFICACY; FEMALE; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; POLLINATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUBLINGUAL IMMUNOTHERAPY; VISUAL ANALOG SCALE;

ADMINISTRATION, SUBLINGUAL; ADULT; ALLERGENS; ANTIBODY SPECIFICITY; ANTIGENS, CD; ANTIGENS, CD80; ANTIGENS, CD86; DOWN-REGULATION; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOTHERAPY; INTERLEUKIN-10; INTERLEUKIN-4; MALE; MIDDLE AGED; MOUTH MUCOSA; RESPIRATORY HYPERSENSITIVITY; VACCINES;

EID: 78650630382     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1002465     Document Type: Article

References (59)

1. Akdis, M., and C. A. Akdis. 2007. Mechanisms of allergen-specific immunotherapy. J. Allergy Clin. Immunol. 119:780-791.
2. Larché, M., C. A. Akdis, and R. Valenta. 2006. Immunological mechanisms of allergen-specific immunotherapy. Nat. Rev. Immunol. 6:761-771.
3. Calderon, M. A., B. Alves, M. Jacobson, B. Hurwitz, A. Sheikh, and S. Durham. 2007. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst. Rev. 1: CD001936.
4. Durham, S. R., S. M. Walker, E. M. Varga, M. R. Jacobson, F. O'Brien, W. Noble, S. J. Till, Q. A. Hamid, and K. T. Nouri-Aria. 1999. Long-term clinical efficacy of grass-pollen immunotherapy. N. Engl. J. Med. 341:468-475.
5. Golden, D. B., K. A. Kwiterovich, A. Kagey-Sobotka, M. D. Valentine, and L. M. Lichtenstein. 1996. Discontinuing venom immunotherapy: outcome after five years. J. Allergy Clin. Immunol. 97:579-587.
6. Des Roches, A., L. Paradis, J. L. Menardo, S. Bouges, J. P. Daurés, and J. Bousquet. 1997. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. J. Allergy Clin. Immunol. 99:450-453.
7. Pajno, G. B., G. Barberio, F. De Luca, L. Morabito, and S. Parmiani. 2001. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy: a six-year follow-up study. Clin. Exp. Allergy 31:1392-1397.
8. Moller, C., S. Dreborg, H. A. Ferdousi, S. Halken, A. Host, L. Jacobsen, A. Koivikko, D. Y. Koller, B. Niggemann, L. A. Norberg, et al. 2002. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT study). J. Allergy Clin. Immunol. 109:251-256.
9. Niggemann, B., L. Jacobsen, S. Dreborg, H. A. Ferdousi, S. Halken, A. Høst, A. Koivikko, D. Koller, L. A. Norberg, R. Urbanek, et al; PAT Investigator Group. 2006. Five-year follow-up on the PAT study: specific immunotherapy and long-term prevention of asthma in children. Allergy 61:855-859.
10. Abramson, M. J., R. M. Puy, and J. M. Weiner. 2003. Allergen immunotherapy for asthma. Cochrane Database Syst. Rev. 4: CD001186.
11. Scadding, G., and S. Durham. 2009. Mechanisms of sublingual immunotherapy. J. Asthma 46:322-334.
12. Nouri-Aria, K. T., P. A. Wachholz, J. N. Francis, M. R. Jacobson, S. M. Walker, L. K. Wilcock, S. Q. Staple, R. C. Aalberse, S. J. Till, and S. R. Durham. 2004. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J. Immunol. 172:3252-3259.
13. Mothes, N., M. Heinzkill, K. J. Drachenberg, W. R. Sperr, M. T. Krauth, Y. Majlesi, H. Semper, P. Valent, V. Niederberger, D. Kraft, and R. Valenta. 2003. Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Clin. Exp. Allergy 33:1198-1208.
14. Jutel, M., M. Akdis, F. Budak, C. Aebischer-Casaulta, M. Wrzyszcz, K. Blaser, and C. A. Akdis. 2003. IL-10 and TGF-β cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur. J. Immunol. 33:1205-1214.
15. Pilette, C., K. T. Nouri-Aria, M. R. Jacobson, L. K. Wilcock, B. Detry, S. M. Walker, J. N. Francis, and S. R. Durham. 2007. Grass pollen immunotherapy induces an allergen-specific IgA2 antibody response associated with mucosal TGF-b expression. J. Immunol. 178:4658-4666.
16. Ebner, C., U. Siemann, B. Bohle, M. Willheim, U. Wiedermann, S. Schenk, F. Klotz, H. Ebner, D. Kraft, and O. Scheiner. 1997. Immunological changes during specific immunotherapy of grass pollen allergy: reduced lymphoproliferative responses to allergen and shift from TH2 to TH1 in T-cell clones specific for Phl p 1, a major grass pollen allergen. Clin. Exp. Allergy 27:1007-1015.
17. Hawrylowicz, C. M., and A. O'Garra. 2005. Potential role of interleukin-10-secreting regulatory T cells in allergy and asthma. Nat. Rev. Immunol. 5:271-283.
18. Wilson, D. R., A. M. Irani, S. M. Walker, M. R. Jacobson, I. S. Mackay, L. B. Schwartz, and S. R. Durham. 2001. Grass pollen immunotherapy inhibits seasonal increases in basophils and eosinophils in the nasal epithelium. Clin. Exp. Allergy 31:1705-1713.
19. Durham, S. R., S. Ying, V. A. Varney, M. R. Jacobson, R. M. Sudderick, I. S. Mackay, A. B. Kay, and Q. A. Hamid. 1996. Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma. J. Allergy Clin. Immunol. 97:1356-1365.
20. Potter, P. C. 2006. Update on sublingual immunotherapy. Ann. Allergy Asthma Immunol. 96 (Suppl. 1): S22-S25.
21. Wilson, D. R., M. T. Lima, and S. R. Durham. 2005. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy 60:4-12.
22. Dahl, R., A. Kapp, G. Colombo, J. G. R. de Monchy, S. Rak, W. Emminger, B. Riis, P. M. Grønager, and S. R. Durham. 2008. Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. J. Allergy Clin. Immunol. 121:512-518, e2.
23. Ott, H., J. Sieber, R. Brehler, R. Fölster-Holst, A. Kapp, L. Klimek, O. Pfaar, and H. Merk. 2009. Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT study. Allergy 64:1394-1401.
24. Novembre, E., E. Galli, F. Landi, C. Caffarelli, M. Pifferi, E. De Marco, S. E. Burastero, G. Calori, L. Benetti, P. Bonazza, et al. 2004. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J. Allergy Clin. Immunol. 114:851-857.
25. Marogna, M., D. Tomassetti, A. Bernasconi, F. Colombo, A. Massolo, A. D. Businco, G. W. Canonica, G. Passalacqua, and S. Tripodi. 2008. Preventive effects of sublingual immunotherapy in childhood: an open randomized controlled study. Ann. Allergy Asthma Immunol. 101:206-211.
26. Didier, A., H. J. Malling, M. Worm, F. Horak, S. Jäger, A. Montagut, C. André, O. de Beaumont, and M. Melac. 2007. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J. Allergy Clin. Immunol. 120:1338-1345.
27. Durham, S. R., W. H. Yang, M. R. Pedersen, N. Johansen, and S. Rak. 2006. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J. Allergy Clin. Immunol. 117:802-809.
28. Wahn, U., A. Tabar, P. Kuna, S. Halken, A. Montagut, O. de Beaumont, and M. Le Gall; SLIT Study Group. 2009. Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J. Allergy Clin. Immunol. 123:160-166, e3.
29. Lima, M. T., D. Wilson, L. Pitkin, A. Roberts, K. Nouri-Aria, M. Jacobson, S. Walker, and S. Durham. 2002. Grass pollen sublingual immunotherapy for seasonal rhinoconjunctivitis: a randomized controlled trial. Clin. Exp. Allergy 32:507-514.
30. Marcucci, F., L. Sensi, G. Di Cara, C. Incorvaia, and F. Frati. 2005. Dose dependence of immunological response to sublingual immunotherapy. Allergy 60:952-956.
31. Rossi, R. E., G. Monasterolo, G. Coco, L. Silvestro, and D. Operti. 2007. Evaluation of serum IgG4 antibodies specific to grass pollen allergen components in the follow up of allergic patients undergoing subcutaneous and sublingual immunotherapy. Vaccine 25:957-964.
32. André, C., M. Perrin-Fayolle, M. Grosclaude, P. Couturier, D. Basset, J. Cornillon, D. Piperno, B. Girodet, R. Sanchez, C. Vallon, et al. 2003. A double-blind placebo-controlled evaluation of sublingual immunotherapy with a standardized ragweed extract in patients with seasonal rhinitis: evidence for a dose-response relationship. Int. Arch. Allergy Immunol. 131:111-118.
33. Passalacqua, G., M. Albano, L. Fregonese, A. Riccio, C. Pronzato, G. S. Mela, and G. W. Canonica. 1998. Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis. Lancet 351:629-632.
34. Savolainen, J., L. Jacobsen, and E. Valovirta. 2006. Sublingual immunotherapy in children modulates allergen-induced in vitro expression of cytokine mRNA in PBMC. Allergy 61:1184-1190.
35. Ciprandi, G., I. Cirillo, D. Fenoglio, G. Marseglia, and M. A. Tosca. 2006. Sublingual immunotherapy induces spirometric improvement associated with IL-10 production: preliminary reports. Int. Immunopharmacol. 6:1370-1373. (Pubitemid 43868186)
36. Akdis, C. A., I. B. Barlan, N. Bahceciler, and M. Akdis. 2006. Immunological mechanisms of sublingual immunotherapy. Allergy 61 (Suppl. 81):11-14.
37. Cosmi, L., V. Santarlasci, R. Angeli, F. Liotta, L. Maggi, F. Frosali, O. Rossi, P. Falagiani, G. Riva, S. Romagnani, et al. 2006. Sublingual immunotherapy with Dermatophagoides monomeric allergoid down-regulates allergen-specific immunoglobulin E and increases both interferon-gamma-and interleukin-10-production. Clin. Exp. Allergy 36:261-272.
38. Bohle, B., T. Kinaciyan, M. Gerstmayr, A. Radakovics, B. Jahn-Schmid, and C. Ebner. 2007. Sublingual immunotherapy induces IL-10 producing T regulatory cells, allergen-specific T-cell tolerance and immune deviation. J. Allergy Clin. Immunol. 120:770-713.
39. Fanta, C., B. Bohle, W. Hirt, U. Siemann, F. Horak, D. Kraft, H. Ebner, and C. Ebner. 1999. Systemic immunological changes induced by administration of grass pollen allergens via the oral mucosa during sublingual immunotherapy. Int. Arch. Allergy Immunol. 120:218-224.
40. Scadding, G. W., M. H. Shamji, M. R. Jacobson, D. I. Lee, D. Wilson, M. T. Lima, L. Pitkin, C. Pilette, K. Nouri-Aria, and S. R. Durham. 2010. Sublingual grass pollen immunotherapy is associated with increases in sublingual Foxp3-expressing cells and elevated allergen-specific immunoglobulin G4, immunoglobulin A and serum inhibitory activity for immunoglobulin E-facilitated allergen binding to B cells. Clin. Exp. Allergy 40:598-606.
41. Kuo, C. H., W. L. Wang, Y. T. Chu, M. S. Lee, and C. H. Hung. 2009. Sublingual immunotherapy in children: an updated review. Pediatr. Neonatol. 50:44-49.
42. Rolinck-Werninghaus, C., M. Kopp, C. Liebke, J. Lange, U. Wahn, and B. Niggemann. 2005. Lack of detectable alterations in immune responses during sublingual immunotherapy in children with seasonal allergic rhinoconjunctivitis to grass pollen. Int. Arch. Allergy Immunol. 136:134-141.
43. Dehlink, E., T. Eiwegger, M. Gerstmayr, E. Kampl, B. Bohle, K. W. Chen, S. Vrtala, R. Urbanek, and Z. Szépfalusi. 2006. Absence of systemic immunologic changes during dose build-up phase and early maintenance period in effective specific sublingual immunotherapy in children. Clin. Exp. Allergy 36:32-39.
44. Moingeon, P., T. Batard, R. Fadel, F. Frati, J. Sieber, and L. Van Overtvelt. 2006. Immune mechanisms of allergen-specific sublingual immunotherapy. Allergy 61:151-165. (Pubitemid 43381824)
45. Lombardi, C., C. Incorvaia, M. Braga, G. Senna, G. W. Canonica, and G. Passalacqua. 2009. Administration regimens for sublingual immunotherapy to pollen allergens: what do we know? Allergy 64:849-854.
46. Piconi, S., D. Trabattoni, M. Saresella, E. Iemoli, M. Schenal, A. Fusi, M. Borelli, L. Chen, A. Mascheri, and M. Clerici. 2007. Effects of specific immunotherapy on the B7 family of costimulatory moclecules in allergic inflammation. J. Immunol. 178:1931-1937.
47. Bousquet, P. J., C. Combescure, J. M. Klossek, J. P. Daurès, and J. Bousquet. 2009. Change in visual analog scale score in a pragmatic randomized cluster trial of allergic rhinitis. J. Allergy Clin. Immunol. 123:1349-1354.
48. Bousquet, P. J., C. Combescure, F. Neukirch, J. M. Klossek, H. Méchin, J. P. Daures, and J. Bousquet. 2007. Visual analog scales can assess the severity of rhinitis graded according to ARIA guidelines. Allergy 62:367-372.
49. Dong, H., G. Zhu, K. Tamada, and L. Chen. 1999. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat. Med. 5:1365-1369.
50. Trabattoni, D., M. Saresella, M. Biasin, A. Boasso, L. Piacentini, P. Ferrante, H. Dong, R. Maserati, G. M. Shearer, L. Chen, and M. Clerici. 2003. B7-H1 is up-regulated in HIV infection and is a novel surrogate marker of disease progression. Blood 101:2514-2520.
51. Keir, M. E., L. M. Francisco, and A. H. Sharpe. 2007. PD-1 and its ligands in T-cell immunity. Curr. Opin. Immunol. 19:309-314.
52. Brooks, D. G., S. J. Ha, H. Elsaesser, A. H. Sharpe, G. J. Freeman, and M. B. Oldstone. 2008. IL-10 and PD-L1 operate through distinct pathways to suppress T-cell activity during persistent viral infection. Proc. Natl. Acad. Sci. USA 105:20428-20433.
53. Francisco, L. M., V. H. Salinas, K. E. Brown, V. K. Vanguri, G. J. Freeman, V. K. Kuchroo, and A. H. Sharpe. 2009. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J. Exp. Med. 206:3015-3029.
54. Wang, L., K. Pino-Lagos, V. C. de Vries, I. Guleria, M. H. Sayegh, and R. J. Noelle. 2008. Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+CD4+ regulatory T cells. Proc. Natl. Acad. Sci. USA 105:9331-9336.
55. Rosewich, M., J. Schulze, O. Eickmeier, T. Telles, M. A. Rose, R. Schubert, and S. Zielen. 2010. Tolerance induction after specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid A in children. Clin. Exp. Immunol. 160:403-410.
56. Pipet, A., K. Botturi, D. Pinot, D. Vervloet, and A. Magnan. 2009. Allergenspecific immunotherapy in allergic rhinitis and asthma: mechanisms and proof of efficacy. Respir. Med. 103:800-812.
57. van Neerven, R. J., T. Wikborg, G. Lund, B. Jacobsen, A. Brinch-Nielsen, J. Arnved, and H. Ipsen. 1999. Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4+ T cells by inhibiting serum-IgEfacilitated allergen presentation. J. Immunol. 163:2944-2952.
58. Francis, J. N., L. K. James, G. Paraskevopoulos, C. Wong, M. A. Calderon, S. R. Durham, and S. J. Till. 2008. Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity. J. Allergy Clin. Immunol. 121:1120-1125, e2.
59. Martínez-Cócera, C., J. Sastre, M. Cimarra, S. Quirce, M. Fernández-Rivas, A. Enríquez-Matas, M. Rodríguez-Alvarez, and S. J. Martín. 2010. Immunotherapy with a Phleum pratense allergen extract induces an immune response to a grass-mix allergen extract. J. Investig. Allergol. Clin. Immunol. 20:13-19.